Medigene

Medigene AG, founded in 1994, is a biotechnology company headquartered in Munich, Germany, focusing on developing highly innovative personalized T-cell therapies for various forms and stages of cancer. Medigene’s candidate TCR-T cell therapy, MDG1011, is currently in Phase I/II clinical trials for hematological malignancies, with the first patient already treated. The specific indications for this clinical trial include acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and multiple myeloma (MM).